Takeda completes 18-month CEO transition with Julie Kim appointment
Takeda Pharmaceutical (TAK) completed its planned 18-month leadership transition, with shareholders electing Julie Kim as Representative Director, President, and CEO at the company's 150th annual general meeting.
Takeda Pharmaceutical Company Limited () completed its 18-month leadership transition by appointing Julie Kim as Representative Director, President, and CEO following a shareholder vote at the company's 150th annual general meeting [1]. Shareholders elected Kim as a new internal director to the board, formalizing the final step of the succession process [2].
The appointment concludes a structured handover that began in early 2025, when Takeda announced the transition plan. Kim had served in senior leadership roles at the Japanese pharmaceutical company prior to her election, though the company has not disclosed her most recent title during the transition period.
Continue reading
3 more paragraphs for subscribers.
Free readers get a daily preview and the weekly long-form. Premium unlocks every brief in full, AM & PM editions, alerts, and the archive.